Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Miragen Therapeutics Inc (MGEN)

Miragen Therapeutics Inc (MGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 89,928
  • Shares Outstanding, K 3,908
  • Annual Sales, $ 4,460 K
  • Annual Income, $ -41,870 K
  • 60-Month Beta 1.66
  • Price/Sales 47.83
  • Price/Cash Flow N/A
  • Price/Book 4.16
Trade MGEN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -10.65
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 03/10/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -2.61
  • Number of Estimates 4
  • High Estimate -1.27
  • Low Estimate -5.67
  • Prior Year -4.65
  • Growth Rate Est. (year over year) +43.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.02 +43.59%
on 12/29/20
25.67 -10.36%
on 01/14/21
+3.06 (+15.34%)
since 12/18/20
3-Month
7.08 +225.00%
on 10/22/20
25.67 -10.36%
on 01/14/21
+15.21 (+195.00%)
since 10/19/20
52-Week
4.66 +393.25%
on 03/19/20
34.05 -32.42%
on 01/30/20
+13.11 (+132.42%)
since 01/17/20

Most Recent Stories

More News
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc....

MGEN : 23.01 (-0.09%)
miRagen Enters into License Agreement with Xencor for use of Xtendâ„¢ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology

MGEN : 23.01 (-0.09%)
miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

BOULDER, Colo., Nov. 10, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a biotechnology company advancing new treatments for patients with diseases that are underserved by current...

MGEN : 23.01 (-0.09%)
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.

Acquisition includes clinical stage anti-IGF - 1R monoclonal antibody, VRDN-001 , intended for the treatment of thyroid eye disease (TED)

MGEN : 23.01 (-0.09%)
miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)

miRagen decides to discontinue further internal development of cobomarsen

MGEN : 23.01 (-0.09%)
miRagen Announces Leadership Transition and Review of Strategic Alternatives

Lee Rauch appointed President and CEO, following resignation by William Marshall

MGEN : 23.01 (-0.09%)
miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL

BOULDER, Colo., Aug. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted...

MGEN : 23.01 (-0.09%)
miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates

BOULDER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted...

MGEN : 23.01 (-0.09%)
miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

BOULDER, Colo., Aug. 04, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies,...

MGEN : 23.01 (-0.09%)
miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics

FRANKFURT, Germany and BOULDER, Colo., July 28, 2020 (GLOBE NEWSWIRE) -- Goethe University, University Hospital Frankfurt and miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical...

MGEN : 23.01 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder,...

See More

Key Turning Points

3rd Resistance Point 24.55
2nd Resistance Point 24.22
1st Resistance Point 23.62
Last Price 23.01
1st Support Level 22.69
2nd Support Level 22.36
3rd Support Level 21.76

See More

52-Week High 34.05
Last Price 23.01
Fibonacci 61.8% 22.82
Fibonacci 50% 19.36
Fibonacci 38.2% 15.89
52-Week Low 4.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar